can tirzepatide cause kidney damage improves outcomes in T2DM with increased CV risk FDA SIDE EFFECTS UPDATE: Kidney

doi:10.1016/j.appet.2011.05.107

GLP-1 RA treatment might be expected to improve HF outcome by augmenting glucose uptake by the myocardium, a potentially important mechanism in HF as fatty acid metabolism is down-regulated, and adenosine triphosphate synthesis is more dependent on glucose

FFA, Free fatty acid

Of note, all the studies undertaken in the OCC included in this meta-analysis used 3 T MRS strength, whereas there was variation in MRS strength across the other brain regions (7 T was used for two MFC studies, with 3 T used for three MFC studies)

Head-to-head research from 2024 gives tirzepatide the edge in average results